Menu Search
Equities

NovaBridge Biosciences

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0VY:FRA

NovaBridge Biosciences

Actions
  • Price (EUR)2.64
  • Today's Change-0.04 / -1.49%
  • Shares traded10.86k
  • 1 Year change+186.96%
  • Beta1.6109
Data delayed at least 15 minutes, as of Feb 16 2026 07:19 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.

  • Revenue in USD (TTM)0.00
  • Net income in USD-26.33m
  • Incorporated2016
  • Employees32.00
  • Location
    NovaBridge BiosciencesSuite 400, 2440 Research BlvdROCKVILLE 20850United StatesUSA
  • Phone+1 (301) 670-2800
  • Websitehttps://www.novabridge.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.